

6. Kakefuda, T. & Yamamoto, H. *Proc. natn. Acad. Sci. U.S.A.* **75**, 415–419 (1978).
7. Drinkwater, N. R., Miller, J. A., Miller, E. C., & Yang, N.-C. *Cancer Res.* **38**, 3247–3255 (1978).
8. Gamper, H. B., Tung, A. S.-C., Straub, K., Bariholomew, J. C. & Calvin, M. *Science* **197**, 671–673 (1977).
9. Bolivar, F. *et al. Gene* **2**, 95–113 (1978).
10. Sutcliffe, J. G. *et al.* (in preparation).
11. Sakakibara, Y. & Tomizawa, J. *Proc. natn. Acad. Sci. U.S.A.* **71**, 802–806 (1974).
12. Inselburg, J. *Proc. natn. Acad. Sci. U.S.A.* **71**, 2256–2259 (1974).
13. Tomizawa, J., Sakakibara, Y. & Kakefuda, T. *Proc. natn. Acad. Sci. U.S.A.* **71**, 2260–2264 (1974).
14. Hsu, W.-T., Lin, J. S. E., Harvey, R. G. & Weiss, S. B. *Proc. natn. Acad. Sci. U.S.A.* **74**, 3335–3339 (1977).
15. Blair, D. G., Sherratt, D. J., Clewell, D. B. & Helsinki, D. R. *Proc. natn. Acad. Sci. U.S.A.* **69**, 2518–2522 (1972).
16. Mizusawa, H., Tanaka, S., Kobayashi, M. & Koike, K. *Biochem. biophys. Res. Commun.* **74**, 570–576 (1977).

## Suppression of a yeast *amber* mutation in *Escherichia coli*

THE complementation of *Escherichia coli* auxotrophs by cloned eukaryotic genes<sup>1–4</sup> makes it possible to use standard bacterial genetic techniques to study these eukaryotic genes. Here, we describe the cloning of a *Saccharomyces cerevisiae* (yeast) gene with an *amber* suppressible allele. Reversion and suppression properties of this allele are examined in growing *E. coli* cells.

The yeast *his3* gene coding for imidazoleglycerolphosphate (IGP) dehydratase was cloned as a hybrid of bacteriophage  $\lambda$  which complemented *hisB* auxotrophs of *E. coli* lacking the analogous activity<sup>1</sup>. The wild type yeast *his3* gene is transcribed and translated in *E. coli* with high fidelity to produce an enzyme activity strongly resembling the activity found in yeast cells<sup>2</sup>. Complementation analysis of many derivatives containing *his3* sequences indicates that the *his3* structural gene is localised to a region of approximately 700 base pairs<sup>3</sup>. The length and location of this *E. coli* complementation unit is similar to the region homologous to the 650 base poly(A)-containing RNA species found in yeast cells (K. S., unpublished).

Genetic analysis in *E. coli* of the yeast *his3* gene depends on the availability of cloned derivatives which are nonfunctional. Mutant *his3* genes which are nonfunctional in *his3*<sup>-</sup> yeast cells are also nonfunctional when cloned and propagated in *E. coli*; that is, they do not complement *E. coli hisB* auxotrophs<sup>2</sup>. The order of two such *his3* lesions has been established by a three-factor cross of the bacteriophage  $\lambda$  hybrids containing the cloned mutant genes<sup>2</sup>. Non-complementing deletions of the yeast *his3* gene spontaneously generated during lytic growth of a bacteriophage  $\lambda his3$  hybrid have been isolated<sup>5</sup> by the method of Parkinson and Huskey<sup>6</sup>. The physical locations of the yeast lesions have been determined by deletion mapping in *E. coli*<sup>5</sup>. Deletion mutants which require transcriptional initiation from the  $\lambda$  promoter P<sub>L</sub> for *his3* expression have been used to define a yeast DNA sequence which functions in *E. coli* as a promoter<sup>7</sup>. Derivatives of a  $\lambda his3$  hybrid which overproduces IGP dehydratase activity in *E. coli* have also been isolated (M. Brennan and K. S., unpublished results).

The demonstration that cloned yeast genes can be reintroduced into yeast cells by transformation and expressed<sup>8</sup>

makes it possible to fuse the genetic systems of *E. coli* and *S. cerevisiae*. Recent findings indicate that DNA transformation of yeast can occur by at least three mechanisms (ref. 9 and J. B. Hick, A. Hinnen and G. R. F., unpublished results). Depending on the particular mechanism, transforming DNA can integrate into the yeast chromosomes by homologous recombination and/or replicate autonomously. Introduction of physically and genetically defined cloned *his3* derivatives into yeast cells should be an important tool in elucidating mechanisms of yeast regulation, DNA replication and recombination.

To aid such studies it would be useful to clone a conditionally lethal yeast mutation. Strain constructions would be significantly facilitated and interpretation of experimental results would be strengthened by the conditional nature of the lesion. To isolate a conditionally lethal lesion, 112 independently derived *his3* mutants of yeast<sup>10</sup> were screened for *amber* suppressibility by scoring for histidine prototrophy following mating with *his3*-532 SUP4-2. Three mutants (*his3*-14, *his3*-19 and *his3*-X5-21B) presumably containing internal UAG codons suppressible by tyrosine-inserting tRNAs<sup>11</sup> were isolated. DNA from strain *his3*-X5-21B was cloned in  $\lambda$ gt4 (ref. 12) by the *EcoRI*-DNA ligase method<sup>2</sup>. From this pool of  $\lambda$ gt4 hybrids, a phage containing *his3* sequences was isolated by the plaque filter hybridisation method of Benton and Davis<sup>13</sup>. The 10.1 kb (kilobase pair) *EcoRI* fragment in this phage, Sc2693, is physically indistinguishable from the analogous fragment (Sc2601) which complements *E. coli hisB* mutations.  $\lambda$ gt4-Sc2693 does not complement *hisB*463; therefore, the phage contains a cloned yeast *his3* gene with an *amber* lesion. The *his3* gene is located internally within a 1.7 kb *Bam*HI fragment of Sc2601 DNA<sup>5</sup>. The equivalent *Bam*HI DNA fragments of  $\lambda$  hybrids containing *his3* mutant genes were cloned in the yeast vectors YIp5 and YRp7 (ref. 9). The sources of these cloned mutant genes were  $\lambda$ gt1-Sc2612 (*his3*-38),  $\lambda$ gt6-Sc2679 (*his3*-532) (ref. 2), and  $\lambda$ gt4-Sc2693 (*his3*-X5-21B).

All mutant *his3* genes cloned in these yeast vectors were introduced into the *E. coli* strain *hisB*463 by selection for the plasmid-coded gene for ampicillin resistance. The spontaneous reversion rates in *E. coli* of these yeast lesions were measured and compared to the spontaneous reversion rates in yeast (Table 1). The comparison is complicated by the fact that in these *E. coli* cells, the *his3* genes are presumably present in about 20 copies, and that the expression is only about four times above the single copy level<sup>7</sup>. The reversion rates are measured as His<sup>+</sup> colonies obtained per cell. It is unclear how these numbers are related to number of reversion events per DNA molecule. Multiple copies of *his3*-38 in *hisB*463 cells allow some growth in the absence of histidine. The reversion rate of this lesion in *E. coli* as determined from plasmid hybrids ( $2 \times 10^{-8}$ ) agrees well with the previous results obtained with phage hybrids<sup>2</sup>. The reversion rate of this lesion in yeast is significantly lower ( $< 10^{-9}$ ). *his3*-532 is a very stable lesion in both organisms, though revertants are detected in *E. coli* but not in yeast *his3*-X5-21B reverts in *E. coli* at a significantly lower rate than it reverts in yeast. These results indicate that spontaneous reversion of a given yeast lesion occurs at different rates in yeast and in *E. coli*.

**Table 1** Suppression and reversion characteristics of yeast *his3* lesions

<i>his3</i> lesion	$\lambda$ Hybrid	Plasmid hybrid	<i>hisB</i> ( <i>supF</i> )	<i>his</i> <sup>+</sup> colonies <i>hisB</i>	Yeast
<i>his3</i> -38	$\lambda$ gt1-Sc2612	YIp5-Sc2719	$2 \times 10^{-8}$	$3 \times 10^{-8}$	$< 10^{-9}$
		YRp7-Sc2719	$1 \times 10^{-8}$	$1 \times 10^{-8}$	
<i>his3</i> -532	$\lambda$ gt6-Sc2679	YIp5-Sc2720	$2 \times 10^{-10}$	$1 \times 10^{-10}$	$< 10^{-10}$
		YIp5-Sc2721	1	$3 \times 10^{-9}$	
<i>his3</i> -X5-21B	$\lambda$ gt4-Sc2693	YRp7-Sc2721	1	$1 \times 10^{-9}$	$2 \times 10^{-7}$

As *his3-X5-21B* is suppressed in yeast by a tyrosine-inserting tRNA, suppression in *E. coli* was examined with an analogous tRNA species (*supF*). *hisB463* cells containing the cloned yeast *his3* lesions were lysogenised by a phage ( $\phi 80$  *supF*) containing the *E. coli* gene coding for a tRNA species capable of suppressing amber (UAG) codons<sup>14</sup>. Introduction of the *supF* allele into these *hisB463* derivatives was determined by their ability to plate  $\lambda$ C1857Sam7. *hisB463* cells containing both the *his3-X5-21B* and the *supF* alleles grow in the absence of histidine (Table 1); that is, the *his3* lesion is suppressed by *supF*. This result is not due to an artefact of selection, as both the *his3-X5-21B* and the *supF* alleles were introduced into the *hisB463* host by non-selective means. Furthermore, it confirms the amber suppressibility of the *his3-X5-21B* allele. It is now possible to introduce DNA containing this conditionally lethal yeast gene back into yeast and *E. coli*.

These results indicate that an *E. coli* amber-suppressing tRNA species suppresses a yeast amber lesion in growing *E. coli* cells. It has been previously established that purified yeast suppressor tRNAs, when present in heterologous, eukaryotic, *in vitro* translation systems, suppress prokaryotic (Q $\beta$ ) amber mutations<sup>15,16</sup>. Taken together, these *in vivo* and *in vitro* experiments provide evidence that translational termination and tRNA suppression of nonsense codons are processes which are conserved between prokaryotic and eukaryotic organisms.

KEVIN STRUHL

RONALD W. DAVIS


Department of Biochemistry,  
Stanford University Medical School,  
Stanford, California 94305

GERALD R. FINK

Department of Genetics,  
Cornell University,  
Ithaca, New York 14850

Received 27 December 1978; accepted 12 March 1979.

1. Struhl, K., Cameron, J. R. & Davis, R. W. *Proc. natn. Acad. Sci. U.S.A.* **73**, 1471-1475 (1976).
2. Struhl, K. & Davis, R. W. *Proc. natn. Acad. Sci. U.S.A.* **74**, 5255-5259 (1977).
3. Ratzkin, B. & Carbon, J. *Proc. natn. Acad. Sci. U.S.A.* **74**, 487-491 (1977).
4. Vapnek, D., Hautala, J. A., Jacobson, J. W., Giles, N. H. & Kushner, S. R. *Proc. natn. Acad. Sci. U.S.A.* **74**, 3508-3512 (1977).
5. Struhl, K. & Davis, R. W. *J. molec. Biol.* (in the press).
6. Parkinson, J. S. & Huskey, R. J. *J. molec. Biol.* **56**, 369-384 (1971).
7. Struhl, K. & Davis, R. W. *J. molec. Biol.* (in the press).
8. Hinneen, A., Hicks, J. B. & Fink, G. R. *Proc. natn. Acad. Sci. U.S.A.* **75**, 1929-1933 (1978).
9. Struhl, K., Stinchcomb, D. T., Scherer, S. & Davis, R. W. *Proc. natn. Acad. Sci. U.S.A.* **76**, 1035-1039 (1979).
10. Fink, G. R. *Science* **146**, 525-527 (1964).
11. Stewart, J. W. & Sherman, F. *J. molec. Biol.* **68**, 429-443 (1972).
12. Panasenko, S. M., Cameron, J. R., Davis, R. W. & Lehman, I. R. *Science* **196**, 188-189 (1977).
13. Benton, W. D. & Davis, R. W. *Science* **196**, 180-182 (1977).
14. Russell, R. L. *et al. J. molec. Biol.* **47**, 1-13 (1970).
15. Capecchi, M. R., Hughes, J. H. & Wahl, G. M. *Cell* **6**, 269-277 (1975).
16. Gesteland, R. F. *et al. Cell* **7**, 381-390 (1976).



**Fig. 1** Unstained living cultures photographed with phase contrast-optics. The structures are typical and the illustrations representative of the experimental results, a, C57 +/+, normal multinucleate myotube; b, C57 *dy*<sup>23</sup>/*dy*<sup>23</sup>, large syncytial myotube; c, C57 *dy/dy*, a definite multinucleate myotube; d, 129 *dy/dy*, characteristic pseudostraps with discrete uninucleate cells. All photographs were taken at 4 d *in vitro* in identical conditions.

(pseudostraps) in place of multinucleate syncytial myotubes<sup>2</sup>. MacPike, however, showed<sup>3</sup> that muscular dystrophies caused by these two alleles carried in the same genetic background (C57BL/6J) were similar when assessed histologically. I have, therefore, investigated how the process of myogenesis *in vitro* (which can be considered to be another independent function of the muscle) is affected not only by the two allelic mutants but also by the genetic background. The *dy* dystrophy was known to be histologically similar in either the C57BL/6J or 129/ReJ background<sup>3</sup> but surprisingly C57BL/6J *dy/dy* cultures gave normal myogenesis while 129/ReJ *dy/dy* cultures again produced pseudostraps.

The mice used in this series of experiments were C57BL/6J *dy*<sup>23</sup>/*dy*<sup>23</sup>, C57BL/6J *dy/dy*, C57BL/6J +/+ and 129/ReJ *dy/dy* at 2, 3, 4 and 5 months of age. Cultures were obtained from 4 day crush lesions as described previously<sup>1</sup>. Daily examination for a period of 8 days was carried out blind; 48 cultures of each genotype were assessed. As before, the pattern of growth during the first 3 days was one of proliferation and explant spreading. Myotubes, increasing in size and number, developed by days 4 to 8 in all three C57BL/6J genotypes including the *dy* mutant (Fig. 1a, b, c). The 129/ReJ *dy/dy* showed without exception the characteristic pseudostraps (Fig. 1d) and the occasional small myocyte during the first 3 days.

*In vitro* the 129/ReJ *dy* muscle attempts to form myotubes but does not succeed<sup>1</sup>. However, the same muscle in a more complex organotypic culture of fetal spinal cord and muscle exhibits some regeneration<sup>4</sup> although it is much less than normal muscle in the same conditions. Furthermore, the *dy* muscle cells cultured as a low density monolayer<sup>5</sup> produce apparently normal myogenic colonies which contain well differentiated muscle fibres. Clearly, myogenesis from dystrophic muscle is extremely susceptible to environmental conditions. But it is also

## Genotype control of the dystrophin gene in mice

MUTANTS of the dystrophin gene (*dy*) in mouse suffer from progressive skeletal muscle loss, together with inadequate repair or regeneration<sup>6</sup>. In 1974 I reported a distinctive phenotypic difference between two dystrophic mutant alleles with respect to myogenesis *in vitro*<sup>1</sup>. Homozygous *dy*<sup>23</sup> mice gave cultures in which there was apparently normal myogenesis, whereas mice homozygous for *dy* gave cultures which contained large numbers of grouped uninucleate myoblasts